VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q56811309  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000309.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q56811309‏
024 ‎‡a  0000-0003-4773-053X‏ ‎‡2  orcid‏
024 ‎‡a  7103015771‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q56811309‏
100 0 ‎‡a  Juan C Montero‏ ‎‡c  researcher (ORCID 0000-0003-4773-053X)‏ ‎‡9  en‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Juan C Montero‏ ‎‡c  onderzoeker‏ ‎‡9  nl‏
670 ‎‡a  Author's Achilles' heel of triple negative cancer‏
670 ‎‡a  Author's Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin‏
670 ‎‡a  Author's Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer‏
670 ‎‡a  Author's Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2‏
670 ‎‡a  Author's Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node.‏
670 ‎‡a  Author's Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms‏
670 ‎‡a  Author's CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia‏
670 ‎‡a  Author's Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme‏
670 ‎‡a  Author's Erk5 is activated and acts as a survival factor in mitosis.‏
670 ‎‡a  Author's Erratum: Achilles' heel of triple negative cancer‏
670 ‎‡a  Author's Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.‏
670 ‎‡a  Author's Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target‏
670 ‎‡a  Author's Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.‏
670 ‎‡a  Author's Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling‏
670 ‎‡a  Author's In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.‏
670 ‎‡a  Author's In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.‏
670 ‎‡a  Author's Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.‏
670 ‎‡a  Author's Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.‏
670 ‎‡a  Author's Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors.‏
670 ‎‡a  Author's Molecular pathways: P-Rex in cancer.‏
670 ‎‡a  Author's Multifunctional role of Erk5 in multiple myeloma‏
670 ‎‡a  Author's Multisite phosphorylation of P-Rex1 by protein kinase C.‏
670 ‎‡a  Author's N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity.‏
670 ‎‡a  Author's Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies‏
670 ‎‡a  Author's Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer‏
670 ‎‡a  Author's Neuregulins and cancer.‏
670 ‎‡a  Author's P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.‏
670 ‎‡a  Author's PDCD4 limits prooncogenic neuregulin-ErbB signaling‏
670 ‎‡a  Author's Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.‏
670 ‎‡a  Author's Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.‏
670 ‎‡a  Author's Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.‏
670 ‎‡a  Author's Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.‏
670 ‎‡a  Author's Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer‏
670 ‎‡a  Author's Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer.‏
670 ‎‡a  Author's Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors‏
670 ‎‡a  Author's Targeting the EGF/HER Ligand-Receptor System in Cancer.‏
670 ‎‡a  Author's The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.‏
670 ‎‡a  Author's The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.‏
670 ‎‡a  Author's The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.‏
670 ‎‡a  Author's Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains‏
670 ‎‡a  Author's Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease‏
670 ‎‡a  Author's Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase‏
670 ‎‡a  Author's Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts‏
909 ‎‡a  (scopus) 7103015771‏ ‎‡9  1‏
909 ‎‡a  (orcid) 000000034773053x‏ ‎‡9  1‏
919 ‎‡a  neuregulinsandcancer‏ ‎‡A  Neuregulins and cancer.‏ ‎‡9  1‏
919 ‎‡a  prex1participatesinneuregulinerbbsignaltransductionanditsexpressioncorrelateswithpatientoutcomeinbreastcancer‏ ‎‡A  P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.‏ ‎‡9  1‏
919 ‎‡a  pdcd4limitsprooncogenicneuregulinerbbsignaling‏ ‎‡A  PDCD4 limits prooncogenic neuregulin-ErbB signaling‏ ‎‡9  1‏
919 ‎‡a  phosphokinaseprofileofcolorectaltumorsguidesintheselectionofmultikinaseinhibitors‏ ‎‡A  Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.‏ ‎‡9  1‏
919 ‎‡a  phosphokinaseprofileoftriplenegativebreastcancerandandrogenreceptorsignaling‏ ‎‡A  Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.‏ ‎‡9  1‏
919 ‎‡a  phosphorylationofprex1atserine1169participatesinigf1rsignalinginbreastcancercells‏ ‎‡A  Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.‏ ‎‡9  1‏
919 ‎‡a  regulationoftheprometastaticneuregulinmmp13axisbysrcfamilykinasestherapeuticimplications‏ ‎‡A  Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.‏ ‎‡9  1‏
919 ‎‡a  surfaceomeanalysesuncovercd98hcasanantibodydrugconjugatetargetintriplenegativebreastcancer‏ ‎‡A  Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer‏ ‎‡9  1‏
919 ‎‡a  syntheticlethalityinteractionbetweenaurorakinasesandchek1inhibitorsinovariancancer‏ ‎‡A  Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer.‏ ‎‡9  1‏
919 ‎‡a  targetingbasallikebreasttumorswithbromodomainandextraterminaldomainbetandpololikekinaseinhibitors‏ ‎‡A  Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors‏ ‎‡9  1‏
919 ‎‡a  targetingtheegfherligandreceptorsystemincancer‏ ‎‡A  Targeting the EGF/HER Ligand-Receptor System in Cancer.‏ ‎‡9  1‏
919 ‎‡a  extracellularlinkerofproneuregulinalpha2cisrequiredforefficientsortingandjuxtacrinefunction‏ ‎‡A  The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.‏ ‎‡9  1‏
919 ‎‡a  immunoglobulinlikedomainofneuregulinspotentiateserbb3her3activationandcellularproliferation‏ ‎‡A  The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.‏ ‎‡9  1‏
919 ‎‡a  insulinlikegrowthfactor1receptorinhibitornvpaew541provokescellcyclearrestandapoptosisinmultiplemyelomacells‏ ‎‡A  The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.‏ ‎‡9  1‏
919 ‎‡a  transautocrinesignalingbymembraneneuregulinsrequirescellsurfacetargetingwhichiscontrolledbymultipledomains‏ ‎‡A  Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains‏ ‎‡9  1‏
919 ‎‡a  transcriptomicprofileinducedinbonemarrowmesenchymalstromalcellsafterinteractionwithmultiplemyelomacellsimplicationsinmyelomaprogressionandmyelomabonedisease‏ ‎‡A  Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease‏ ‎‡9  1‏
919 ‎‡a  transforminggrowthfactorbeta1inducescollagensynthesisandaccumulationviap38mitogenactivatedproteinkinase‏ ‎‡A  Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase‏ ‎‡9  1‏
919 ‎‡a  transforminggrowthfactorbeta1inducescollagensynthesisandaccumulationviap38mitogenactivatedproteinkinasemapkpathwayincultured506e9myoblasts‏ ‎‡A  Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts‏ ‎‡9  1‏
919 ‎‡a  nterminalcleavageofprotgfalphaoccursatthecellsurfacebyataceindependentactivity‏ ‎‡A  N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity.‏ ‎‡9  1‏
919 ‎‡a  multisitephosphorylationofprex1byproteinkinase100‏ ‎‡A  Multisite phosphorylation of P-Rex1 by protein kinase C.‏ ‎‡9  1‏
919 ‎‡a  multifunctionalroleoferk5inmultiplemyeloma‏ ‎‡A  Multifunctional role of Erk5 in multiple myeloma‏ ‎‡9  1‏
919 ‎‡a  molecularpathwaysprexincancer‏ ‎‡A  Molecular pathways: P-Rex in cancer.‏ ‎‡9  1‏
919 ‎‡a  mitoticarrestinducedbyanovelfamilyofdnatopoisomerase2inhibitors‏ ‎‡A  Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors.‏ ‎‡9  1‏
919 ‎‡a  mitogenactivatedproteinkinasedependentandindependentroutescontrolsheddingoftransmembranegrowthfactorsthroughmultiplesecretases‏ ‎‡A  Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.‏ ‎‡9  1‏
919 ‎‡a  inhibitionofsrcfamilykinasesandreceptortyrosinekinasesbydasatinibpossiblecombinationsinsolidtumors‏ ‎‡A  Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.‏ ‎‡9  1‏
919 ‎‡a  invivomurinemodelofacquiredresistanceinmyelomarevealsdifferentialmechanismsforlenalidomideandpomalidomideincombinationwithdexamethasone‏ ‎‡A  In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.‏ ‎‡9  1‏
919 ‎‡a  insilicoanalysisguidesselectionofbetinhibitorsfortriplenegativebreastcancertreatment‏ ‎‡A  In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.‏ ‎‡9  1‏
919 ‎‡a  identificationoftherapeutictargetsinovariancancerthroughactivetyrosinekinaseprofiling‏ ‎‡A  Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling‏ ‎‡9  1‏
919 ‎‡a  extracellularsignalregulatedkinasephosphorylatestumornecrosisfactoralphaconvertingenzymeatthreonine735apotentialroleinregulatedshedding‏ ‎‡A  Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.‏ ‎‡9  1‏
919 ‎‡a  expressionoferk5inearlystagebreastcancerandassociationwithdiseasefreesurvivalidentifiesthiskinaseasapotentialtherapeutictarget‏ ‎‡A  Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target‏ ‎‡9  1‏
919 ‎‡a  expressionof100kitisoformsinmultiplemyelomadifferencesinsignalinganddrugsensitivity‏ ‎‡A  Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.‏ ‎‡9  1‏
919 ‎‡a  erratumachillesheeloftriplenegativecancer‏ ‎‡A  Erratum: Achilles' heel of triple negative cancer‏ ‎‡9  1‏
919 ‎‡a  erk5isactivatedandactsasasurvivalfactorinmitosis‏ ‎‡A  Erk5 is activated and acts as a survival factor in mitosis.‏ ‎‡9  1‏
919 ‎‡a  differentialsheddingoftransmembraneneuregulinisoformsbythetumornecrosisfactoralphaconvertingenzyme‏ ‎‡A  Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme‏ ‎‡9  1‏
919 ‎‡a  cm363anovelnaphthoquinonederivativewhichactsasmultikinasemodulatorandovercomesimatinibresistanceinchronicmyelogenousleukemia‏ ‎‡A  CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia‏ ‎‡9  1‏
919 ‎‡a  cleavageofthetrkaneurotrophinreceptorbymultiplemetalloproteasesgeneratessignallingcompetenttruncatedforms‏ ‎‡A  Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms‏ ‎‡9  1‏
919 ‎‡a  breastcancerdisseminationpromotedbyaneuregulincollagenase3signallingnode‏ ‎‡A  Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node.‏ ‎‡9  1‏
919 ‎‡a  antitumoralactivityofthemithralogec8042intriplenegativebreastcancerlinkedtocellcyclearresting2‏ ‎‡A  Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2‏ ‎‡9  1‏
919 ‎‡a  antitumoractivityofthenovelmultikinaseinhibitorec70124intriplenegativebreastcancer‏ ‎‡A  Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer‏ ‎‡9  1‏
919 ‎‡a  activationoferbb2byoverexpressionorbytransmembraneneuregulinresultsindifferentialsignalingandsensitivitytoherceptin‏ ‎‡A  Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin‏ ‎‡9  1‏
919 ‎‡a  achillesheeloftriplenegativecancer‏ ‎‡A  Achilles' heel of triple negative cancer‏ ‎‡9  1‏
919 ‎‡a  neuregulinexpressioninsolidtumorsprognosticvalueandpredictiveroletoantiher3therapies‏ ‎‡A  Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies‏ ‎‡9  1‏
919 ‎‡a  neuregulinexpressionmodulatesclinicalresponsetotrastuzumabinpatientswithmetastaticbreastcancer‏ ‎‡A  Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  BNE|XX1121306‏
996 ‎‡2  LC|no2012025972‏
996 ‎‡2  BNC|981058524991906706‏
996 ‎‡2  LC|n 96097959‏
996 ‎‡2  BNE|XX887742‏
996 ‎‡2  DNB|110304169X‏
996 ‎‡2  BNCHL|10000000000000000181755‏
996 ‎‡2  SUDOC|119459868‏
996 ‎‡2  LC|no2002043053‏
996 ‎‡2  ISNI|0000000081616958‏
996 ‎‡2  ISNI|0000000358968981‏
996 ‎‡2  ISNI|0000000117788058‏
996 ‎‡2  BNE|XX969153‏
996 ‎‡2  BNC|981058516476106706‏
996 ‎‡2  RERO|A018548209‏
996 ‎‡2  SUDOC|260015067‏
996 ‎‡2  BNC|981058517394806706‏
996 ‎‡2  BNF|14467566‏
996 ‎‡2  DNB|1261014421‏
996 ‎‡2  NUKAT|n 2004027913‏
996 ‎‡2  ISNI|0000000044223442‏
996 ‎‡2  BNE|XX1112713‏
996 ‎‡2  PLWABN|9813222003905606‏
996 ‎‡2  BNE|XX1094177‏
996 ‎‡2  LC|no2001034561‏
996 ‎‡2  BNE|XX1473587‏
996 ‎‡2  SUDOC|10880626X‏
996 ‎‡2  LC|no2021102826‏
996 ‎‡2  J9U|987007440443105171‏
996 ‎‡2  DNB|1168056306‏
996 ‎‡2  BNCHL|10000000000000000854734‏
996 ‎‡2  BNF|12148866‏
996 ‎‡2  BNE|XX1149872‏
996 ‎‡2  BNC|981058616335506706‏
996 ‎‡2  LC|n 82147681‏
996 ‎‡2  BNE|XX1774154‏
996 ‎‡2  BNC|981058596115306706‏
996 ‎‡2  DNB|1156562473‏
996 ‎‡2  ISNI|0000000444600235‏
996 ‎‡2  BNE|XX1320323‏
996 ‎‡2  ISNI|0000000431793875‏
996 ‎‡2  SUDOC|068681852‏
996 ‎‡2  DNB|122302928X‏
996 ‎‡2  BNCHL|10000000000000000836424‏
996 ‎‡2  LC|no2005004107‏
996 ‎‡2  SUDOC|153225750‏
996 ‎‡2  DNB|105423180X‏
996 ‎‡2  BNC|981058601544806706‏
996 ‎‡2  ISNI|0000000001474225‏
996 ‎‡2  BNE|XX969360‏
996 ‎‡2  BNCHL|10000000000000000118350‏
996 ‎‡2  ISNI|0000000116410133‏
996 ‎‡2  SUDOC|25395553X‏
996 ‎‡2  RERO|A013865583‏
996 ‎‡2  BNC|981058530133706706‏
996 ‎‡2  LC|no2009065933‏
996 ‎‡2  BLBNB|000299503‏
996 ‎‡2  BNE|XX1360941‏
996 ‎‡2  JPG|500076336‏
996 ‎‡2  DNB|1175253154‏
996 ‎‡2  SUDOC|204459141‏
996 ‎‡2  ISNI|0000000026601454‏
996 ‎‡2  DNB|1232331309‏
996 ‎‡2  BNCHL|10000000000000000127431‏
996 ‎‡2  LC|n 2023044723‏
996 ‎‡2  NKC|mub20211115258‏
996 ‎‡2  ISNI|0000000048227686‏
996 ‎‡2  PLWABN|9810667502705606‏
996 ‎‡2  LC|no2008141366‏
996 ‎‡2  PLWABN|9813297525305606‏
996 ‎‡2  BIBSYS|10017833‏
996 ‎‡2  NUKAT|n 2017026263‏
996 ‎‡2  ISNI|0000000060973323‏
996 ‎‡2  LC|n 2015001696‏
996 ‎‡2  BNE|XX1236460‏
996 ‎‡2  BNC|981060037848306706‏
996 ‎‡2  BNE|XX4683288‏
996 ‎‡2  BAV|495_339864‏
996 ‎‡2  DNB|1057499242‏
996 ‎‡2  RERO|A016707205‏
996 ‎‡2  ISNI|0000000059988106‏
996 ‎‡2  LC|n 2024031885‏
996 ‎‡2  BIBSYS|6099389‏
996 ‎‡2  DNB|171729129‏
996 ‎‡2  BNE|XX5086856‏
996 ‎‡2  JPG|500239991‏
996 ‎‡2  PTBNP|88006‏
996 ‎‡2  ISNI|0000000024814800‏
996 ‎‡2  BNE|XX5473055‏
996 ‎‡2  BNE|XX1123795‏
996 ‎‡2  BNF|16704054‏
996 ‎‡2  ISNI|000000035664596X‏
996 ‎‡2  SUDOC|193578115‏
996 ‎‡2  BNC|981058510943706706‏
996 ‎‡2  RERO|A003605482‏
996 ‎‡2  LC|no2008077070‏
996 ‎‡2  BNC|981058604944506706‏
996 ‎‡2  BNF|17950764‏
996 ‎‡2  DNB|1219014850‏
996 ‎‡2  SUDOC|183363892‏
996 ‎‡2  ISNI|000000005940449X‏
996 ‎‡2  BNE|XX1271560‏
996 ‎‡2  ISNI|0000000393737150‏
996 ‎‡2  DNB|1056497475‏
996 ‎‡2  PTBNP|531501‏
996 ‎‡2  ISNI|0000000066321457‏
996 ‎‡2  LC|n 00105666‏
996 ‎‡2  ISNI|0000000502709862‏
996 ‎‡2  DNB|1064143377‏
996 ‎‡2  SUDOC|260553786‏
996 ‎‡2  ISNI|0000000062681017‏
996 ‎‡2  BNE|XX4677388‏
996 ‎‡2  LC|n 2012074222‏
996 ‎‡2  LC|nr2002046057‏
996 ‎‡2  RERO|A016835866‏
996 ‎‡2  ISNI|0000000037967603‏
996 ‎‡2  SUDOC|237017946‏
996 ‎‡2  BNC|981058512724206706‏
996 ‎‡2  DNB|173684378‏
996 ‎‡2  BNF|16616888‏
996 ‎‡2  BNE|XX1754155‏
996 ‎‡2  BNE|XX1218978‏
996 ‎‡2  SUDOC|111049261‏
996 ‎‡2  BNCHL|10000000000000000119312‏
996 ‎‡2  J9U|987012851535405171‏
996 ‎‡2  DNB|1057115541‏
996 ‎‡2  BNCHL|10000000000000000202602‏
996 ‎‡2  BNE|XX1247497‏
996 ‎‡2  SUDOC|142326240‏
996 ‎‡2  SUDOC|153409665‏
996 ‎‡2  ISNI|0000000038353283‏
996 ‎‡2  NSK|000431247‏
996 ‎‡2  ISNI|0000000501523249‏
996 ‎‡2  BNE|XX5096138‏
996 ‎‡2  ISNI|0000000031520085‏
996 ‎‡2  LC|n 2003011115‏
996 ‎‡2  LC|no2007005769‏
996 ‎‡2  BNE|XX826869‏
996 ‎‡2  BNE|XX1370378‏
996 ‎‡2  LC|n 2012003394‏
996 ‎‡2  SUDOC|265313406‏
996 ‎‡2  RERO|A006010544‏
996 ‎‡2  BNE|XX5486515‏
996 ‎‡2  LC|n 2020066787‏
996 ‎‡2  LC|nr 89015329‏
996 ‎‡2  BNE|XX1320856‏
996 ‎‡2  LC|n 2018010026‏
996 ‎‡2  NII|DA19872149‏
996 ‎‡2  LC|ns2019000986‏
996 ‎‡2  NTA|152794743‏
996 ‎‡2  PTBNP|1294736‏
996 ‎‡2  J9U|987012781075105171‏
996 ‎‡2  BNCHL|10000000000000000058614‏
996 ‎‡2  ISNI|0000000059346058‏
996 ‎‡2  LC|n 78065475‏
996 ‎‡2  ISNI|0000000059386033‏
996 ‎‡2  ISNI|0000000444548449‏
996 ‎‡2  SUDOC|059913584‏
996 ‎‡2  LC|n 99046959‏
996 ‎‡2  BNC|981058513641006706‏
996 ‎‡2  ISNI|0000000114608285‏
996 ‎‡2  JPG|500026762‏
996 ‎‡2  RERO|A027245707‏
996 ‎‡2  ISNI|0000000361180212‏
996 ‎‡2  ISNI|0000000093964124‏
996 ‎‡2  BNE|XX1057162‏
996 ‎‡2  PTBNP|1470746‏
996 ‎‡2  DNB|133781755‏
996 ‎‡2  BNE|XX1057073‏
996 ‎‡2  BNE|XX1447787‏
996 ‎‡2  SUDOC|123522617‏
996 ‎‡2  BNE|XX1706329‏
996 ‎‡2  NUKAT|n 2021141386‏
996 ‎‡2  LC|no 98071984‏
996 ‎‡2  LC|no2024096666‏
996 ‎‡2  BAV|495_224202‏
996 ‎‡2  LC|n 98096043‏
996 ‎‡2  BNE|XX1037095‏
996 ‎‡2  RERO|A023050569‏
996 ‎‡2  BNCHL|10000000000000000829216‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏